
CLAIMS

1. Use of a glutaminase inhibitor in the manufacture of a medicament for the treatment or prevention of cancer, wherein the medicament is to be conjointly administered with an anticancer agent; wherein the anti-cancer agent is everolimus;
the glutaminase inhibitor is a compound of formula II:



(II), or a pharmaceutically acceptable salt thereof; and
the cancer is renal cell carcinoma, multiple myeloma, triple negative breast cancer, or non-small cell lung cancer.


2. The use of claim 1, wherein the cancer is renal cell carcinoma.

3. The use of claim 1, wherein the cancer is multiple myeloma.

4. The use of claim 1, wherein the cancer is triple negative breast cancer.

5. The use of claim 1, wherein the cancer is non-small cell lung cancer.

6. Use of a glutaminase inhibitor in the manufacture of a medicament for the treatment or prevention of cancer, wherein the medicament is to be conjointly administered with an anticancer agent; wherein the anti-cancer agent is erlotinib;
the glutaminase inhibitor is a compound of formula II:



(II), or a pharmaceutically acceptable salt thereof; and

the cancer is non-small cell lung cancer.

7. The use of claim 6, wherein the non-small cell lung cancer is resistant to erlotinib.